Evolus Inc., of Santa Barbara, Calif., presented data at the American Society of Plastic Surgeons meeting in Orlando, Fla., and the American Society for Dermatologic Surgery meeting in Chicago, from phase II and phase III studies of its botulinum toxin candidate, prabotulinumtoxinA 900 kilodalton neuromodulator, in glabellar lines.